GenVec
| GNVC | Profile | Summary
GenVec,
(GNVC) is a biopharmaceutical company using differentiated,
proprietary technologies to create superior therapeutics and
vaccines. A key component of the company's strategy is to develop
and commercialize products through collaborations. GenVec is working
with leading companies and organizations such as Novartis, Merial,
and the U.S. Government to support a portfolio of product programs
that address the prevention and treatment of a number of significant
human and animal health concerns.
GenVec’s
development programs address therapeutic areas such as hearing loss,
balance disorders, and cancer; as well as vaccines against infectious
diseases including respiratory syncytial virus (RSV), herpes simplex
virus type 2 (HSV-2), dengue fever, influenza, malaria, and human
immunodeficiency virus (HIV).
The
GenVec's Advantage
The
company's core technology has the important advantage of localizing
protein delivery in the body. This is accomplished by using
adenovector platform to locally deliver genes to cells, which then
direct production of the desired protein. This approach reduces side
effects typically associated with systemic delivery of proteins. For
vaccines, the goal is to induce an immune response against a target
protein or antigen. This is accomplished by using an adenovector to
deliver a gene that causes production of an antigen, which then
stimulates the desired immune reaction by the body.
GenVec’s
novel proprietary adenovectors
‒
No
pre existing immune recognition
‒
Built
on rare human and nonhuman adenovirus serotypes
‒
New
GC technology shows superior performance for genetic vaccines
‒
Multiple
capsid modified vectors -AdH technology
‒
Multiple
genes/multiple antigens
‒
Targeted
and specific delivery Proprietary adenovectors and cell lines
‒
Novel
proprietary non replicating adenovirus vectors
•
Very
low sero -prevalence in humans
•
Outstanding
gene/antigen delivery properties
‒
Cell
line master banks and master file with FDA
Hearing
Restoration Molecular Therapeutic
•
Dengue
Virus Genetic Vaccine
•
Foot
and Mouth Virus Genetic Vaccine
•
Malaria
Genetic Vaccine
•
RSV
Genetic Vaccine
•
HSV
Molecular Therapeutic and Genetic Vaccine
A
platform of adenovirus vectors built to meet product needs for
molecular therapeutics and genetic vaccines
Don't
miss the NEXT premium Alert! Sign-up,
Get Alerts, MakeMoney!®
we
received or expecting compensation from the featured company. Our
firm, principals and staff may own/buy/sell/trade stock/securities of
this company. Always Read the full Disclosure/Disclaimer. Thanks.
Disclosure/Disclaimer:-
OxBridge Research publishes sponsored research reports, advertorials
and corporate profiles on its portal and several other
websites/blogs, including this website/blog, owned and operated by
OxBridge and/or its affiliates. OxBridge Research is not a Broker
Dealer or a Registered Financial Adviser in any jurisdiction,
whatsoever. All the information published on its website(s) and/or
distributed to its members via various electronic means is for
general awareness and entertainment purpose only. OxBridge urges
investors to do their own due diligence and consult with their
financial adviser prior to making any investment decision. We are
expecting a payment from the company/a third party/shareholder. We
receive compensation from companies for providing various IR
services, including publication, advertisement,and social media
awareness, therefore our views/opinion are inherently biased. Please
read the full disclosure/disclaimer, if you need assistance contact
Editor@OxBridgeResearch.com
OxbridgeResearch.com,
All Rights Reserved. Trademarks/logos are of their respective owners.
It's
YOUR
money - Invest WISELY
TM
